open access

Vol 86, No 6 (2018)
REVIEWS
Published online: 2018-12-30
Submitted: 2018-10-03
Accepted: 2018-12-20
Get Citation

Idiopathic pulmonary fibrosis coexisting with lung cancer — a review

Michał Zieliński, Piotr Sitek, Dariusz Ziora
DOI: 10.5603/ARM.a2018.0052
·
Pubmed: 30595001
·
Adv Respir Med 2018;86(6):319-326.

open access

Vol 86, No 6 (2018)
REVIEWS
Published online: 2018-12-30
Submitted: 2018-10-03
Accepted: 2018-12-20

Abstract

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with poor prognosis. Although the underlying mechanisms are not fully understood, IPF is connected with lung cancer development, which farther worsens the prognosis. Various papers report IPF and cancer coexistence in 9.8% to even 82% of patients depending on observation period. Contrary to already established guidelines in the general population, there are no widely accepted recommendations on lung cancer treatment in IPF population. At the same time, various oncologic interventions can result in acute exacerbation of IPF. This paper tries to revise the available data on lung cancer in patients with preexisting IPF.

Abstract

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with poor prognosis. Although the underlying mechanisms are not fully understood, IPF is connected with lung cancer development, which farther worsens the prognosis. Various papers report IPF and cancer coexistence in 9.8% to even 82% of patients depending on observation period. Contrary to already established guidelines in the general population, there are no widely accepted recommendations on lung cancer treatment in IPF population. At the same time, various oncologic interventions can result in acute exacerbation of IPF. This paper tries to revise the available data on lung cancer in patients with preexisting IPF.

Get Citation

Keywords

idiopathic pulmonary fibrosis, lung cancer, intersititial pneumonitis

About this article
Title

Idiopathic pulmonary fibrosis coexisting with lung cancer — a review

Journal

Advances in Respiratory Medicine

Issue

Vol 86, No 6 (2018)

Pages

319-326

Published online

2018-12-30

DOI

10.5603/ARM.a2018.0052

Pubmed

30595001

Bibliographic record

Adv Respir Med 2018;86(6):319-326.

Keywords

idiopathic pulmonary fibrosis
lung cancer
intersititial pneumonitis

Authors

Michał Zieliński
Piotr Sitek
Dariusz Ziora

References (64)
  1. Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J. 2017; 50(2).
  2. Lee HE, Myong JP, Kim HR, et al. Incidence and prevalence of idiopathic interstitial pneumonia and idiopathic pulmonary fibrosis in Korea. Int J Tuberc Lung Dis. 2016; 20(7): 978–984.
  3. Raghu G, Chen SY, Hou Q, et al. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old. Eur Respir J. 2016; 48(1): 179–186.
  4. Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment. American Journal of Respiratory and Critical Care Medicine. 2000; 161(2): 646–664.
  5. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6): 788–824.
  6. Raghu G, Remy-Jardin M, Myers JL, et al. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(5): e44–e68.
  7. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018; 6(2): 138–153.
  8. Kato E, Takayanagi N, Takaku Y, et al. Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2018; 4(1).
  9. Teixeira MR, Heim S. Cytogenetic analysis of tumor clonality. Adv Cancer Res. 2011; 112: 127–149.
  10. Cool CD, Groshong SD, Rai PR, et al. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med. 2006; 174(6): 654–658.
  11. Kuwano K, Kunitake R, Kawasaki M, et al. P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1996; 154(2 Pt 1): 477–483.
  12. Uematsu K, Yoshimura A, Gemma A, et al. Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res. 2001; 61(23): 8527–8533.
  13. Sanders Y, Pardo A, Selman M, et al. Thy-1 Promoter Hypermethylation. American Journal of Respiratory Cell and Molecular Biology. 2008; 39(5): 610–618.
  14. Liang H, Gu Y, Li T, et al. Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during idiopathic pulmonary fibrosis. Cell Death Dis. 2014; 5: e1238.
  15. Bamberg A, Redente EF, Groshong SD, et al. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med. 2006; 174(6): 654–658.
  16. Guyard A, Danel C, Théou-Anton N, et al. Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses. Respir Res. 2017; 18(1): 120.
  17. Johnston ID, Prescott RJ, Chalmers JC, et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax. 1997; 52(1): 38–44.
  18. Baumgartner KB, Samet JM, Stidley CA, et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997; 155(1): 242–248.
  19. Kelsen SG, Duan X, Ji R, et al. Cigarette smoke induces an unfolded protein response in the human lung: a proteomic approach. Am J Respir Cell Mol Biol. 2008; 38(5): 541–550.
  20. Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ. 1990; 301(6759): 1015–1017.
  21. Gait R, Maginnis C, Lewis S, et al. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet. 1996; 347(8997): 284–289.
  22. Iwai K, Mori T, Yamada N, et al. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med. 1994; 150(3): 670–675.
  23. Turner-Warwick M, Lebowitz M, Burrows B, et al. Cryptogenic fibrosing alveolitis and lung cancer. Thorax. 1980; 35(7): 496–499.
  24. Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000; 161(1): 5–8.
  25. Matsushita H, Tanaka S, Saiki Y, et al. Lung cancer associated with usual interstitial pneumonia. Pathol Int. 1995; 45(12): 925–932.
  26. Hironaka M, Fukayama M. Pulmonary fibrosis and lung carcinoma: a comparative study of metaplastic epithelia in honeycombed areas of usual interstitial pneumonia with or without lung carcinoma. Pathol Int. 1999; 49(12): 1060–1066.
  27. Mapel DW, Hunt WC, Utton R, et al. Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax. 1998; 53(6): 469–476.
  28. Wells C, Mannino DM. Pulmonary fibrosis and lung cancer in the United States: analysis of the multiple cause of death mortality data, 1979 through 1991. South Med J. 1996; 89(5): 505–510.
  29. Harris JM, Cullinan P, McDonald JC. Does cryptogenic fibrosing alveolitis carry an increased risk of death from lung cancer? J Epidemiol Community Health. 1998; 52(9): 602–603.
  30. Ozawa Y, Suda T, Naito T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009; 14(5): 723–728.
  31. Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015; 147(1): 157–164.
  32. Liu Y, Zhu M, Geng J, et al. Incidence and radiologic-pathological features of lung cancer in idiopathic pulmonary fibrosis. Clin Respir J. 2018; 12(4): 1700–1705.
  33. Lee KJ, Chung MP, Kim YW, et al. Prevalence, risk factors and survival of lung cancer in the idiopathic pulmonary fibrosis. Thorac Cancer. 2012; 3(2): 150–155.
  34. Jacob J, Bartholmai BJ, Rajagopalan S, et al. Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. Eur Respir J. 2017; 50(1).
  35. Kwak N, Park CM, Lee J, et al. Lung cancer risk among patients with combined pulmonary fibrosis and emphysema. Respir Med. 2014; 108(3): 524–530.
  36. Hendriks LEL, Drent M, van Haren EHJ, et al. Lung cancer in idiopathic pulmonary fibrosis patients diagnosed during or after lung transplantation. Respir Med Case Rep. 2012; 5: 37–39.
  37. Ahmed Z, Marshall MB, Kucharczuk JC, et al. Lung cancer in transplant recipients: a single-institution experience. Arch Surg. 2004; 139(8): 902–906.
  38. Collins J, Kazerooni EA, Lacomis J, et al. Bronchogenic carcinoma after lung transplantation: frequency, clinical characteristics, and imaging findings. Radiology. 2002; 224(1): 131–138.
  39. Miura Y, Saito T, Tanaka T, et al. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respir Investig. 2018; 56(1): 72–79.
  40. Mediavilla-Varela M, Boateng K, Noyes D, et al. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC Cancer. 2016; 16: 176.
  41. Caliò A, Lever V, Rossi A, et al. Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis. Histopathology. 2017; 71(5): 725–735.
  42. Aubry MC, Myers JL, Douglas WW, et al. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc. 2002; 77(8): 763–770.
  43. Nagai A, Chiyotani A, Nakadate T, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Tohoku J Exp Med. 1992; 167(3): 231–237.
  44. Joo S, Kim DK, Sim HJe, et al. Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis. J Thorac Dis. 2016; 8(5): 977–984.
  45. Masai K, Tsuta K, Motoi N, et al. Clinicopathological, Immunohistochemical, and Genetic Features of Primary Lung Adenocarcinoma Occurring in the Setting of Usual Interstitial Pneumonia Pattern. J Thorac Oncol. 2016; 11(12): 2141–2149.
  46. Kojima Y, Okudela K, Matsumura M, et al. The pathological features of idiopathic interstitial pneumonia-associated pulmonary adenocarcinomas. Histopathology. 2017; 70(4): 568–578.
  47. Tzouvelekis A, Spagnolo P, Bonella F, et al. Patients with IPF and lung cancer: diagnosis and management. The Lancet Respiratory Medicine. 2018; 6(2): 86–88.
  48. Kondoh Y, Taniguchi H, Kitaichi M, et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med. 2006; 100(10): 1753–1759.
  49. Wood DE, Kazerooni EA, Baum SL, et al. National comprehension cancer network. Lung cancer screening. J Natl Compr Canc Netw. 2012; 10(2): 240–265.
  50. Sato S, Koike T, Hashimoto T, et al. Surgical Outcomes of Lung Cancer Patients with Combined Pulmonary Fibrosis and Emphysema and Those with Idiopathic Pulmonary Fibrosis without Emphysema. Ann Thorac Cardiovasc Surg. 2016; 22(4): 216–223.
  51. Saito Y, Kawai Y, Takahashi N, et al. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2011; 92(5): 1812–1817.
  52. Iwata T, Yoshino I, Yoshida S, et al. West Japan Oncology Group. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study). Respir Res. 2016; 17(1): 90.
  53. Kushibe K, Kawaguchi T, Takahama M, et al. Operative indications for lung cancer with idiopathic pulmonary fibrosis. Thorac Cardiovasc Surg. 2007; 55(8): 505–508.
  54. Kumar P, Goldstraw P, Yamada K, et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg. 2003; 125(6): 1321–1327.
  55. Minegishi Y, Sudoh J, Kuribayasi H, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 2011; 71(1): 70–74.
  56. Watanabe N, Taniguchi H, Kondoh Y, et al. Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration. 2013; 85(4): 326–331.
  57. Kanaji N, Tadokoro A, Kita N, et al. Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival. J Cancer Res Clin Oncol. 2016; 142(8): 1855–1865.
  58. Gottfried M, Bennouna J, Bondarenko I, et al. Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. Target Oncol. 2017; 12(4): 475–485.
  59. Watanabe N, Taniguchi H, Kondoh Y, et al. Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis. Int J Clin Oncol. 2014; 19(2): 260–265.
  60. Minegishi Y, Kuribayashi H, Kitamura K, et al. The feasibility study of Carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias. J Thorac Oncol. 2011; 6(4): 801–807.
  61. Kolek V, Vašáková M, Šterclová M, et al. [Radiotherapy of Lung Tumours in Idiopathic Pulmonary Fibrosis]. Klin Onkol. 2017; 30(4): 303–306.
  62. Ono T, Hareyama M, Nakamura T, et al. The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: a single center experience. Radiat Oncol. 2016; 11: 56.
  63. Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). http://seer.cancer.gov/csr/1975_2009_pops09/ (30.10.2018).
  64. Lee T, Park JiY, Lee HY, et al. Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival. Respir Med. 2014; 108(10): 1549–1555.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl